Individualised risk reduction strategies for patients with COPD
Symposium Chairs: Guy Brusselle (Ghent, Belgium), Ian Douglas Pavord (Oxford, United Kingdom)
Aims: To provide an introduction to the clinically important inflammatory phenotypes of COPD, show that the blood eosinophil count is a valid biomarker of risk and risk reduction with inhaled steroids, review the recent findings of studies on inhaled steroid add-on in cohorts that were stratified by baseline blood eosinophil count and detail the factors that associate with a positive response to macrolides.
Target audience: Clinicians, and primary and secondary care physicians.